Impact of the <sup>18</sup>F-FDG-PET/MRI on Metastatic Staging in Patients with Hepatocellular Carcinoma: Initial Results from 104 Patients
Optimal HCC therapeutic management relies on accurate tumor staging. Our aim was to assess the impact of <sup>18</sup>F-FDG-WB-PET/MRI on HCC metastatic staging, compared with the standard of care CT-CAP/liver MRI combination, in patients with HCC referred on a curative intent or before...
Main Authors: | Mathilde Vermersch, Sébastien Mulé, Julia Chalaye, Athena Galletto Pregliasco, Berivan Emsen, Giuliana Amaddeo, Aurélien Monnet, Alto Stemmer, Laurence Baranes, Alexis Laurent, Vincent Leroy, Emmanuel Itti, Alain Luciani |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-09-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/17/4017 |
Similar Items
-
Glutamate-Evoked Ca<sup>2+</sup> Responses in the Rat Suprachiasmatic Nucleus: Involvement of Na<sup>+</sup>/K<sup>+</sup>-ATPase and Na<sup>+</sup>/Ca<sup>2+</sup>-Exchanger
by: Pi-Cheng Cheng, et al.
Published: (2023-03-01) -
Heterotridentate Organomonophosphines in Pt(κ<sup>3</sup>–X<sup>1</sup>P<sup>1</sup>X<sup>2</sup>)(Y) (X<sup>1,2</sup> = N<sup>1,2</sup> or S<sup>1,2</sup>), Pt(κ<sup>3</sup>–P<sup>1</sup>N<sup>1</sup>X<sup>1</sup>)(Y) (X<sup>1</sup> = O, C, S or Se) Pt(κ<sup>3</sup>–P<sup>1</sup>S<sup>1</sup>Cl<sup>1</sup>)(Cl) and Pt(κ<sup>3</sup>–P<sup>1</sup>Si<sup>1</sup>N<sup>1</sup>)(OL)—Structural Aspects
by: Milan Melník, et al.
Published: (2022-12-01) -
Impact of <sup>18</sup>F-FDG PET/CT in Predicting Recurrence in Neurolymphomatosis
by: Megumi Uemichi, et al.
Published: (2021-09-01) -
Na<sup>+</sup>,K<sup>+</sup>-ATPase with Disrupted Na<sup>+</sup> Binding Sites I and III Binds Na<sup>+</sup> with Increased Affinity at Site II and Undergoes Na<sup>+</sup>-Activated Phosphorylation with ATP
by: Hang N. Nielsen, et al.
Published: (2024-01-01) -
Organomonophosphines in Pt(η<sup>3</sup>-X<sup>1</sup>X<sup>2</sup>X<sup>3</sup>)(PR<sub>3</sub>), (X = N<sup>1</sup>, N<sup>2</sup>, N<sup>3</sup>; S<sup>1</sup>, S<sup>2</sup>, S<sup>3</sup>; or Te<sup>1</sup>, Te<sup>2</sup>, Te<sup>3</sup>) Derivatives: Structural Aspects
by: Milan Melník, et al.
Published: (2023-06-01)